Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Osteoid osteoma of the hook of the hamate presenting as ulnar-sided wrist pain: A case report.

Radiology case reports·2020

Same author

An eruption of yellow-red papules on the trunk, arms, and legs of an adult.

Dermatology practical & conceptual·2018

Same author

Halo nevus: review of the literature and clinicopathologic findings.

International journal of dermatology·2015

Same author

Colorectal microcarcinoids in association with long-term exposure to urinary content: a case report and review of the literature.

Case reports in pathology·2015

Same author

A rare soft tissue tumor masquerading as a parathyroid adenoma in a patient with birt-hogg-dubé syndrome and multiple cervical endocrinopathies.

Case reports in pathology·2015

Same author

Longitudinal melanonychia of the toenail.

JAMA dermatology·2014

Search research articles

Related Experiment Video

Updated: Apr 25, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

BRAF mutation testing in solid tumors: a methodological comparison.

Grace W Weyant¹, Jeffrey D Wisotzkey², Floyd A Benko¹

¹Department of Pathology, Penn State College of Medicine-Hershey Medical Center, Hershey, Pennsylvania.

The Journal of Molecular Diagnostics : JMD

|August 19, 2014

Summary

This summary is machine-generated.

The INFINITI KRAS-BRAF assay accurately detects BRAF mutations in solid tumors, showing 100% concordance with established methods like Sanger sequencing and the cobas test.

More Related Videos

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Apr 25, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

Oncology
Molecular Diagnostics
Genetics

Background:

Solid tumor genotyping is crucial for characterizing proto-oncogene mutations.
Sanger sequencing has been the traditional method, but new assays are emerging.
Companion diagnostic and laboratory-developed tests offer alternative approaches.

Purpose of the Study:

To evaluate and validate the analytical performance of the INFINITI KRAS-BRAF assay.
To compare the BRAF mutational status concordance of the INFINITI assay with reference methods.
To assess the INFINITI assay's accuracy and repeatability.

Main Methods:

DNA extraction from FFPE tissue specimens.
Multiplex PCR amplification and allele-specific primer extension with fluorescent labeling.
Hybridization to a microarray, signal detection, and analysis.

Main Results:

The INFINITI KRAS-BRAF assay demonstrated 100% concordance with the cobas 4800 BRAF V600 Mutation Test and Sanger sequencing.
The assay's sensitivity was equivalent to the cobas assay.
Repeatability was high, with at least 95% accuracy in detecting BRAF alleles.

Conclusions:

The INFINITI KRAS-BRAF assay is a reliable and accurate method for BRAF mutation detection.
It is comparable to traditional sequencing and FDA-approved companion diagnostic assays.
This assay provides a viable alternative for solid tumor genotyping.